Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Strategy in Infant Neuroblastoma (INES 99.2/99.3)
NCT00025610Phase 2Completed
- Sponsor
- European Infant Neuroblastoma Study Group
- Start
- Jul 1999
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of carboplatin, etoposide, cyclophosphamide, doxorubicin and vincristine in neuroblastoma (2 arms), sponsored by European Infant Neuroblastoma Study Group. Primary endpoints: Event-Free Survival at 5 years and Overall Survival at 5 years. Started Jul 1999; status: completed.
02
Drugs
carboplatinetoposidecyclophosphamidedoxorubicinvincristine
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT00025610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025610.